Tanabe Pharma Corporation: Parkinson Disease trials

The registry lists 13 Parkinson Disease studies with Tanabe Pharma Corporation as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 7Phase 2 4Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's DiseaseActive, not recruitingNCT02726386Phase 2Results posted
• A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's DiseaseCompletedNCT02577523Phase 2Results posted
• A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease PatientsCompletedNCT01883505Phase 2Results posted
• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsActive, not recruitingNCT04006210Phase 3
• A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral SuspensionWithdrawnNCT03462043Phase 3
• A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor FluctuationsWithdrawnNCT02782481Phase 3
• A Sequential Two-Part, Open-Label Study in Healthy Male and Female SubjectsCompletedNCT02604914Phase 1
• A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)CompletedNCT02486432Phase 1
• A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease PatientsCompletedNCT02096601Phase 1
• A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) PatientsCompletedNCT01725802Phase 1
• Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy VolunteersCompletedNCT01486628Phase 1
• A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease PatientsCompletedNCT01229332Phase 1/2
• Safety, Tolerability and Pharmacokinetic Profile of Levodopa Administered With Continuous Administration of ND0611CompletedNCT01103011Phase 1